CD137 (4-1BB)-Based Cancer Immunotherapy on Its 25th Anniversary

Dec 28, 2022 | Magazine: Cancer Discovery

Ignacio Melero 1 2 3 4 , Miguel F Sanmamed 1 2 3 4 , Javier Glez-Vaz 1 2 , Carlos Luri-Rey 1 2 , Jun Wang 5 , Lieping Chen 6

Abstract

CD137 (4-1BB) is a costimulatory receptor of T and natural killer lymphocytes whose activity can be exploited in cancer immunotherapy strategies as discovered 25 years ago.

Following initial attempts that met unacceptable toxicity, new waves of constructs acting agonistically on CD137 are being developed in patients, offering signs of clinical and pharmacodynamic activity with tolerable safety profiles.

CITATION Cancer Discov. 2023 Mar 1;13(3):552-569. doi: 10.1158/2159-8290.CD-22-1029

see publication in pubmed

Our authors

Imagen Dr. Ignacio Melero Bermejo, Inmunología

Dr. Ignacio Melero Bermejo Curriculum

Codirector Immunology and Immunotherapy Department

Navarre headquarters

Dr. Miguel Fernández de Sanmamed Gutiérrez Curriculum

Specialist Medical Oncology Department

Navarre headquarters